Back to top
more

Synergy Pharmaceuticals, Inc. (SGYP)

(Delayed Data from NSDQ)

$0.03 USD

0.03
NA

0.00 (0.00%)

Updated Mar 7, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals

by Zacks Equity Research

Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.

Synergy Pharmaceuticals (SGYP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synergy Pharma (SGYP) delivered earnings and revenue surprises of -7.69% and -29.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Synergy Pharmaceuticals (SGYP) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Synergy Pharma (SGYP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

by Zacks Equity Research

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.

    Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.

      Synergy Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

      by Zacks Equity Research

      Synergy Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

        Are Options Traders Betting on a Big Move in Synergy Pharmaceuticals (SGYP) Stock?

        by Zacks Equity Research

        Investors in Synergy Pharmaceuticals (SGYP) need to pay close attention to the stock based on moves in the options market lately.

          Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

          by Zacks Equity Research

          Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

            Synergy Pharmaceuticals (SGYP) Reports Q2 Loss, Tops Revenue Estimates

            by Zacks Equity Research

            Synergy Pharma (SGYP) delivered earnings and revenue surprises of 29.41% and 20.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

              Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?

              by Zacks Equity Research

              Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.

                Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options

                by Zacks Equity Research

                Investors in Synergy Pharmaceuticals (SGYP) need to pay close attention to the stock based on moves in the options market lately.

                  Allergan Requests Shareholders to Veto Management Change

                  by Zacks Equity Research

                  Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.

                    Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options

                    by Zacks Equity Research

                    Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.

                      Options Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) Stock

                      by Zacks Equity Research

                      Investors in Synergy Pharmaceuticals (SGYP) need to pay close attention to the stock based on moves in the options market lately.

                        Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales

                        by Zacks Equity Research

                        Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.

                          Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options

                          by Zacks Equity Research

                          Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.

                            Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected

                            by Zacks Equity Research

                            Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.

                              Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs

                              by Zacks Equity Research

                              Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.

                                The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals

                                  Ironwood Succeeds in Diabetic Hypertension Phase II Study

                                  by Zacks Equity Research

                                  Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

                                    Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View

                                    by Zacks Equity Research

                                    Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.

                                      Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

                                      by Zacks Equity Research

                                      Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

                                        Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher

                                        by Zacks Equity Research

                                        Synergy Pharmaceuticals (SGYP) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

                                          Allergan Reports Positive New Data on Irritable Bowl Drug

                                          by Zacks Equity Research

                                          Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).

                                            Allergan's Irritable Bowel Drug Viberzi Approved in Canada

                                            by Zacks Equity Research

                                            Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)